C WorldWide Group Holding A S trimmed its stake in Boston Scientific Corporation (NYSE:BSX) by 3.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 367,194 shares of the medical equipment provider’s stock after selling 14,278 shares during the quarter. C WorldWide Group Holding A S’s holdings in Boston Scientific Corporation were worth $10,711,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Swiss National Bank boosted its stake in Boston Scientific Corporation by 2.9% in the second quarter. Swiss National Bank now owns 5,584,930 shares of the medical equipment provider’s stock valued at $154,814,000 after acquiring an additional 156,800 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Boston Scientific Corporation by 10.5% in the second quarter. Wells Fargo & Company MN now owns 9,157,768 shares of the medical equipment provider’s stock valued at $253,854,000 after acquiring an additional 867,983 shares during the last quarter. Sit Investment Associates Inc. boosted its stake in Boston Scientific Corporation by 37.8% in the third quarter. Sit Investment Associates Inc. now owns 141,710 shares of the medical equipment provider’s stock valued at $4,134,000 after acquiring an additional 38,855 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its stake in Boston Scientific Corporation by 35,016.2% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock valued at $84,337,000 after acquiring an additional 3,033,800 shares during the last quarter. Finally, LS Investment Advisors LLC boosted its stake in Boston Scientific Corporation by 5.8% in the third quarter. LS Investment Advisors LLC now owns 40,621 shares of the medical equipment provider’s stock valued at $1,185,000 after acquiring an additional 2,209 shares during the last quarter. Hedge funds and other institutional investors own 90.45% of the company’s stock.

Boston Scientific Corporation (BSX) traded down $0.23 during trading on Friday, reaching $28.36. 6,526,000 shares of the company were exchanged, compared to its average volume of 6,809,734. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. The company has a market cap of $38,943.84, a price-to-earnings ratio of 23.25, a PEG ratio of 2.19 and a beta of 1.00. Boston Scientific Corporation has a twelve month low of $19.67 and a twelve month high of $29.93.

Boston Scientific Corporation (NYSE:BSX) last issued its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.31. The firm had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a net margin of 9.55% and a return on equity of 23.60%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.27 EPS. research analysts anticipate that Boston Scientific Corporation will post 1.25 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/boston-scientific-corporation-bsx-shares-sold-by-c-worldwide-group-holding-a-s/1698318.html.

A number of research firms have weighed in on BSX. Royal Bank Of Canada reiterated a “buy” rating and issued a $31.00 target price on shares of Boston Scientific Corporation in a research note on Tuesday, November 7th. SunTrust Banks, Inc. set a $34.00 target price on shares of Boston Scientific Corporation and gave the company a “buy” rating in a research note on Tuesday, October 31st. Zacks Investment Research cut shares of Boston Scientific Corporation from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. BMO Capital Markets boosted their target price on shares of Boston Scientific Corporation from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Finally, Canaccord Genuity started coverage on shares of Boston Scientific Corporation in a research note on Tuesday, October 24th. They issued a “buy” rating and a $36.00 target price on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $30.77.

In other news, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $26.87, for a total value of $416,485.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Timothy A. Pratt sold 10,000 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $28.22, for a total transaction of $282,200.00. Following the completion of the transaction, the executive vice president now directly owns 164,681 shares in the company, valued at approximately $4,647,297.82. The disclosure for this sale can be found here. Insiders sold a total of 508,864 shares of company stock worth $14,581,669 in the last three months. Insiders own 0.74% of the company’s stock.

Boston Scientific Corporation Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.